Looks like they have some suppresive qualities. This study was not done with s-4 but its a start. Seems most of the research for the drug purposes want it to suppress LH. To lower test and andr. stimulation to protect or shrink the prostate, yet still have anabolic propreties to keep quality of life high.
Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator
This article is not included in your organization's subscription. However, you may be able to access this article under your organization's agreement with Elsevier.
Fabrice Piua, , , Luis R. Gardella, Thomas Sona, Nathalie Schliengerb, Birgitte W. Lundb, Hans H. Schiffera, Kim E. Vanovera, Robert E. Davisa, Roger Olssonb and Stefania Risso Bradleya
aACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard, San Diego, CA 92121, USA
bACADIA Pharmaceuticals AB, Medeon Science Park, S205 12 Malmo, Sweden
Received 31 July 2007; revised 19 September 2007; accepted 16 November 2007. Available online 22 November 2007.
Abstract
Because of the limitations and liabilities of current testosterone therapies, non-steroidal tissue-selective androgen receptor modulators may provide a clinically meaningful advance in therapy. Using a functional cell-based assay AC-262536 was identified as a potent and selective AR ligand, with partial agonist activity relative to the natural androgen testosterone. A 2-week chronic study in castrated male rats indicated that AC-262536 significantly improves anabolic parameters in these animals, especially in stimulating the growth of the levator ani and in suppressing elevated LH levels. In sharp contrast to testosterone, AC-262536 has weak androgenic effects, as measured by prostate and seminal vesicle weights. Thus, AC-262536 represents a novel class of selective androgen receptor modulators (SARMs) with beneficial anabolic effects